This protocol addresses metastatic pheochromocytoma/paraganglioma (mPPGL) in patients with bone metastases — a common and clinically significant manifestation that requires dedicated, targeted management alongside systemic disease control.
Bone involvement occurs in at least 60–70% of patients with mPPGL and is limited to bone alone in approximately 20% of cases, making skeletal disease a central consideration in this setting.
Management of bone metastases in mPPGL involves bone-targeted therapy. When skeletal disease progresses or new bone involvement develops, an evidence-based escalation step exists — the full protocol details the approach and sequence.
DOI: 10.1097/MPA.0000000000001792
The skeletal system is 1 of the most common sites of metastatic disease in mPPGL, occurring in at least 60% to 70% of patients and limited to bone alone in 20% of patients.
If the bone disease progresses on 1 bone-targeted agent, and/or new bone disease develops, consideration may be given to switching to the alternative bone-targeted agent.
View source ↗